🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Binimetinib

    United Therapeutics Europe Ltd

    Metastatic Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  2. Binimetinib

    United Therapeutics Europe Ltd

    Locally Advanced Pancreatic Carcinoma

    phase 2 small molecule terminated

    1 trial

  3. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  4. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  5. Bivalent killed oral cholera vaccine

    International Peace Maternity and Child Health Hospital

    Cholera

    phase 2 mab active

    1 trial

  6. Blautix

    4D Molecular Therapeutics

    Irritable Bowel Syndrome

    phase 2 mab completed

    1 trial

  7. Blinatumomab

    Takeda

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

    phase 2 mab active

    1 trial

  8. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  9. BoNT A

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  10. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  11. Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Brentuximab Vedotin

    United Therapeutics Europe Ltd

    Ann Arbor Stage IB Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  13. Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule terminated

    1 trial

  14. Briquilimab

    Jasper Therapeutics

    Chronic Urticaria

    phase 2 small molecule active

    1 trial

  15. Briquilimab

    Jasper Therapeutics

    Urticaria Chronic

    phase 2 small molecule active

    1 trial

  16. Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  17. Bupivacaine HCI without epinephrine

    Heron Therapeutics

    Post-Operative Pain

    phase 2 small molecule completed

    1 trial

  18. Buprenorphine and Outpatient Parenteral Antibiotic Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Use

    phase 2 small molecule completed

    1 trial

  19. Byooviz 10 mg/ml solution for injection

    Samsung Bioepis NL B.V.

    Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)

    phase 2 small molecule active

    1 trial

  20. C1 Esterase Inhibitor Injection [Cinryze]

    Takeda

    Subarachnoid Hemorrhage, Aneurysmal

    phase 2 small molecule active

    1 trial

  21. C105

    COGNITION THERAPEUTICS INC

    Cognition Disorders

    phase 2 small molecule completed

    1 trial

  22. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Australia Pty Ltd

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  23. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Australia Pty Ltd

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  24. CAN-2409

    Candel Therapeutics

    Malignant Glioma

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources